Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Mingyu Jin, Shaoying Yuan, Yiming Yuan, Luqi YiFrontiers in Oncology 2021 · DOI

TL;DR

This meta-analysis confirms that the Systemic Immune-Inflammation Index (SII)—a simple calculation based on standard blood counts—is a powerful independent predictor of overall survival in patients with Renal Cell Carcinoma (RCC). While it doesn't significantly correlate with progression-free survival across all groups, a high SII is a clear red flag for more aggressive disease and poor clinical risk profiles.

What Problem Does This Paper Address?

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer, and its prognosis remains a challenge; roughly 25–30% of patients already have metastases at the time of diagnosis. While immunotherapy and targeted treatments have improved outcomes, clinicians desperately need reliable, "low-hanging fruit" biomarkers to identify high-risk patients early.

The Systemic Immune-Inflammation Index (SII) has emerged as a candidate. It’s a "liquid biopsy" of sorts that combines three immune cell types—neutrophils, platelets, and lymphocytes—into a single score. However, previous studies on SII in kidney cancer have yielded conflicting results. This paper performs a systematic meta-analysis to provide a definitive look at whether SII actually matters for RCC prognosis and how it relates to the physical characteristics of the tumor (clinicopathological features).

Methods

The authors conducted a systematic review and meta-analysis following standard guidelines. They searched major databases (PubMed, Embase, Web of Science, and Cochrane Library) for English-language studies published up to October 2021.

  • The Metric: SII is calculated using the formula: $(Platelets \times Neutrophils) / Lymphocytes$.
  • Statistical Approach: They used Hazard Ratios (HRs) for survival outcomes and Odds Ratios (ORs) for clinicopathological features.
  • Models: They applied random-effects models when high heterogeneity ($I^2 > 50\%$) was present and fixed-effects models otherwise.
  • Quality Control: Study quality was assessed using the Newcastle-Ottawa Scale (NOS), with all included studies scoring $\ge 6$, indicating high quality.

Datasets

As a meta-analysis, the "dataset" consists of 10 previously published studies.

  • Total Cohort: 3,180 patients.
  • Geographic Diversity: Studies spanned Turkey, Italy, India, China, Japan, Austria, and Poland.
  • Clinical Context: Eight studies focused on metastatic RCC (mRCC), while two looked at localized disease.
  • Follow-up: Median follow-up times ranged from 15 to 84 months.

Key Insights and Ideas

  • The Balance of Power: The SII is fascinating because it captures the "tug-of-war" between the body's pro-tumor and anti-tumor forces. Neutrophils and platelets often facilitate tumor growth, angiogenesis, and metastasis, while lymphocytes are the primary soldiers in the anti-cancer immune response. A high SII suggests the pro-tumor inflammatory environment is winning.
  • Survival vs. Progression: Interestingly, while a high SII strongly predicted Overall Survival (OS), it was not a statistically significant predictor for Progression-Free Survival (PFS) or Cancer-Specific Survival (CSS) in the primary analysis. This suggests SII might be a better indicator of the patient's general systemic health and inflammatory burden rather than just the immediate speed of tumor growth.
  • Correlation with Aggression: High SII wasn't just a number on a lab report; it correlated with "scarier" pathology, specifically higher Fuhrman grades (G3–G4), which indicate more abnormal-looking, faster-growing cells.

Key Results

  • Overall Survival (OS): Patients with a high SII had a significantly higher risk of death (HR 1.75, 95% CI 1.33–2.30, $p < 0.001$).
  • Clinical Risk: There was a massive correlation between high SII and "poor risk" status according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria (OR 19.12).
  • Tumor Grade: High SII was associated with higher Fuhrman grades (OR 1.80).
  • Demographics: High SII was more frequently observed in male patients (OR 1.51).
  • Subgroup Nuance: In a subgroup analysis, the authors found that an SII cut-off of $\le 730$ was actually a better predictor for PFS/DFS than higher cut-offs, suggesting that the "threshold" for what constitutes a dangerous SII might need to be standardized.

Limitations and Future Work

The authors acknowledge several hurdles:

  1. Sample Size: Only 10 studies were included, which limits the power of subgroup analyses (especially for CSS).
  2. Retrospective Design: Most included studies were retrospective, which introduces inherent selection bias.
  3. Cut-off Inconsistency: There is no universal "high" SII value. Included studies used thresholds ranging from 529 to 1,375.
  4. Future Directions: Large-scale, prospective multicenter trials are needed to validate these findings and, crucially, to determine the optimal clinical cut-off value for SII before it can be used in daily practice.

Summary updated

Abstract

A high SII was independently associated with poor survival outcomes in patients with RCC. Additionally, an elevated SII indicated more aggressive disease. The SII may serve as a useful cost-effective prognostic indicator in patients with RCC.
BibTeX
@inproceedings{jin2021prognostic,
  author = {Mingyu Jin and Shaoying Yuan and Yiming Yuan and Luqi Yi},
  title = {{Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.735803},
}
Figure